SecBot SecBot
8-K ·Filed Jun 11, 2026

KALV

KalVista Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed5mo ago SEC0001140361-26-024949
Killer combo: M&A completed + management change
Actionable Insight • Neutral

The acquisition is complete and KALV common stock is no longer trading. Remaining public shareholders who did not tender will receive $27.00 per share through the merger. Convertible note holders should monitor conversion procedures under the first supplemental indenture for cash settlement. No further trading or SEC reporting obligations for KalVista common stock are expected after the Form 15 deregistration.

DirectionNeutral
Confidencehigh
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through a tender offer and subsequent merger, closing on June 11, 2026. A total of 43,152,532 shares (approximately 77.8% of outstanding) were validly tendered. As a result, KalVista became a wholly owned subsidiary of Chiesi, its common stock ceased trading on Nasdaq, and all remaining shares were converted into the right to receive the same $27.00 per share cash consideration.

Key Financial Metrics

Deal Type
acquisition

Key Facts

  • Tender offer expired June 10, 2026; 43,152,532 shares (77.8%) validly tendered
  • Merger completed June 11, 2026 via Section 251(h) of Delaware law without stockholder vote
  • Stock consideration: $27.00 per share in cash
  • KalVista common stock delisted from Nasdaq Global Market effective prior to June 11, 2026 trading
  • Entire board of directors resigned; John Hess (Purchaser's director) became sole director
  • Beneficial ownership equity plans and ESPP terminated effective at closing
  • Convertible note holders receive $1,606.28 per $1,000 principal (base conversion) or $1,739.78 (make-whole conversion) in cash

Financial Impact

All outstanding KalVista common shares acquired for $27.00 per share in cash, totaling approximately $1.5 billion based on ~55.5M fully diluted shares

stock price (converged to $27.00)market capitalization (eliminated)common stock listing (delisted)convertible notes (converted to cash)

Risk Factors

  • Delisting and deregistration eliminate liquidity for common stock; remaining holders must wait for merger consideration payment
  • Potential excise tax gross-up exposure for CFO Brian Piekos under Section 4999, magnitude unknown
  • Integration risk for Chiesi in commercializing EKTERLY (sebetralstat) across global markets

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
54% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-024949
Document: ny20075902x2_8k.htm0001140361-26-024949
Document: ny20075902x2_ex4-2.htm0001140361-26-024949
Document: ny20075902x2_ex99-1.htm0001140361-26-024949
Document: ny20075902x2_ex3-1.htm0001140361-26-024949
Document: 0001140361-26-024949-index-headers.html0001140361-26-024949
Document: 0001140361-26-024949-index.html0001140361-26-024949
Document: 0001140361-26-024949.txt0001140361-26-024949

Track record

12 reports on KALV

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
  2. Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
  3. Jun 11, 202622w ago 8-K Neutral 5/10 Viewing Entry $26.99 No price data
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
  5. May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
  6. May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
  7. Apr 29, 202628w ago 8-K Bullish 8/10 Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
  8. Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
  9. Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
  10. Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026